HMGB1 ELISA

Being a Severe Acute Respiratory Syndrome disease, COVID-19 might be causing great damage to the lung and if involved with comorbidities might lead to death. Statistics openly published with media indicate that despite being on ventilation still roundabout 85% of these patients still die. A recent review shows how HMGB1 might link into the severity of the pathology of SARS-CoV-2 in the lungs.

“…The focus of this review is a possible role of the proinflammatory, endogenous mediator high mobility group box 1 protein (HMGB1) in the pathogenesis of COVID-19. …”

“…on the functional role HMGB1/TLR4-mediated neuroinflammation in brain diseases of both infectious and sterile origin. COVID-19 also emerge with features of neuroinflammation including fever, loss of small, taste and appetite. We suggest that HMGB1 contributes to these symptoms via TLR4 expression…”

“…HMGB1 transfection complexes were not toxic to cultured cells. It is thus conceivable that the RNA of SARS-CoV-2 virus might reach the cellular cytosol through HMGB1-assisted transport, as previously discussed…”

“…Chloroquine phosphate-based therapy in China and hydroxychloroquine treatment in South Korea have been reported to improve outcome in COVID-19 infections…Chloroquine has been demonstrated to decrease HMGB1 secretion from activated innate immunity cells. Chloroquine-mediated alkalinization of lysosomes inhibiting HMGB1-caused lysosomal leakage is a plausible mechanism that might be beneficial for COVID-19 treatment to prevent lysosomal leakage...”

Multi-tasker of the innate immune system

Over the years, HMGB1 has increasingly attracted the attention of basic as well as clinical researchers and has become one of the most intriguing molecules within the complete arsenal of proteins of the innate immune system.

IBL International’s HMGB1 ELISA, which has been developed by Shino-Test Corporation, Japan, in cooperation with Prof. Dr. Ikuro Maruyama, Kagoshima University, is the worldwide renown assay to quantify HMGB1 in any experimental setting.

HMGB1 is a nuclear protein that can bind and bend DNA, but it can also be released to the extracellular environment where it exerts additional functions. The unraveling of the post-translational modifications has led to a better understanding of the mechanism of its translocation and its function within the immune system. It will now also allow more in-depth studies into the role of HMGB1 in numerous pathologies, including

Autoimmune diseases

Sepsis

Cancer

Diabetes

Cardial infarction

Stroke

... any inflammatory process

HMGB1

Through its collaboration with HMGB1 experts from academia and commercial partners, IBL International is at the forefront of new developments. We at IBL offer the most complete range of products - including the highly sensitive ELISA for the quantitative measurement of HMGB1 - which have been widely used and are cited in many publications.

Figure: HMGB1 biology by the current state of scientific knowledge (click to enlarge)

Excerpt from the Instructions for Use

The HMGB1 ELISA Kit was developed by Shino-Test Corporation, Japan, in cooperation with Prof. Dr. Ikuro Maruyama, Kagoshima University. The product is exclusively distributed worldwide by IBL International except in Japan, China (incl. Hong Kong) and Taiwan.

HMGB1 is an ubiquitous protein that can be found in all animals in the cytosol and the nucleus of the cells.As a nucleus-binding protein it regulates amongst other things the gene transcription.HMGB1 plays a major role in the pathogenesis of a lot of diseases.So HMGB1 is important in the development and survival of tumours. It regulates by interaction with RAGE autophagy. It is late mediator in sepsis. It organizes cross-talk of NKs and DCs in viral infections. These findings represent only a small overview of HMGB1's role in medical research.

For concrete data please consult the Instruction for Use in the download box on the right side.